Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance
Open Access
- 15 November 2022
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (11) , 925-933
Abstract
Background: To evaluate the impact of concomitant use of probiotic BB-12 in metformin-treated patients with type 2 diabetes or prediabetes on glycemic control, metformin-related gastrointestinal side effects, and treatment compliance. Methods: A total of 156 patients (mean [standard deviation] age: 50.9 [9.9 years], 74.4% females) with newly diagnosed type 2 diabetes or prediabetes were randomly assigned to receive either metformin alone (n = 84, MET group) or metformin plus Bifidobacterium animalis subsp. lactis (BB-12) probiotic (n = 72, MET-PRO group). Data on body mass index (kg/m2), fasting blood glucose (mg/dL), blood lipids, and glycated hemoglobin (HbA1c) levels were recorded at baseline and at the third month of therapy. Data on gastrointestinal intolerance symptoms and treatment noncompliance were also recorded during post-treatment week 1 to week 4. Results: MET-PRO versus MET therapy was associated with a significantly higher rate of treatment compliance (91.7% vs 71.4%, P = .001), greater reduction from baseline HbA1c values (0.9 [0.4-1.6] vs 0.4 [0-1.6] %, P < .001) and lower likelihood of gastrointestinal intolerance symptoms, including abdominal pain (P = .031 to <.001), diarrhea (P = .005 to <.001) and bloating (P = .010 to <.001). Noncompliance developed later (at least 15 days after the therapy) in a significantly higher percentage of patients in the MET group (P = .001 for 15–21 days and P = .002 for 22–28 days). Conclusion: In conclusion, the present study proposes the benefit of combining probiotics with metformin in the treatment of patients with T2D or prediabetes in terms of improved glycemic control and treatment adherence rather than correction of dyslipidemia or weight reduction. Cite this article as: Şahin K, Şahintürk Y, Köker G, et al. Metformin with versus without concomitant probiotic therapy in newly diagnosed patients with type 2 diabetes or prediabetes: A comparative analysis in relation to glycemic control, gastrointestinal side effects, and treatment compliance. Turk J Gastroenterol. 2022;33(11):925-933.Keywords
This publication has 29 references indexed in Scilit:
- Probiotics as beneficial agents in the management of diabetes mellitus: a systematic reviewDiabetes/Metabolism Research and Reviews, 2015
- Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose LevelsJournal of Diabetes Science and Technology, 2015
- Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese miceBeneficial Microbes, 2014
- Effect of Metformin on Metabolic Improvement and Gut MicrobiotaApplied and Environmental Microbiology, 2014
- The anti-diabetic activity of Bifidobacterium lactis HY8101 in vitro and in vivoJournal of Applied Microbiology, 2014
- The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12®Microorganisms, 2014
- Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker ratsJournal of Endocrinology, 2014
- Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes StudyDiabetes Care, 2012
- Prebiotic Fiber Increases Hepatic Acetyl CoA Carboxylase Phosphorylation and Suppresses Glucose-Dependent Insulinotropic Polypeptide Secretion More Effectively When Used with Metformin in Obese Rats,The Journal of Nutrition, 2012
- Well-Being and Gastrointestinal Symptoms among Patients Referred to Endoscopy Owing to Suspected Duodenal UlcerScandinavian Journal of Gastroenterology, 1995